US Stock Market Move | ADC drug's new indication achieves "global first launch" in China. Astrazeneca PLC Sponsored ADR (AZN.US) rose nearly 5% in early trading.

On Friday, Astrazeneca PLC Sponsored ADR (AZN.US) rose nearly 5% in early trading, reaching $192.17. On the news front, on March 27, Astrazeneca PLC Sponsored ADR announced that trastuzumab deruxtecan (Enhertu), a drug jointly developed with Daiichi Sankyo, has officially been approved by the Chinese National Medical Products Administration for use in neoadjuvant therapy for high-risk HER2-positive stage II or III breast cancer in adult patients. This is the first global approval for this indication, with China approving it before other global markets such as the US and Europe. Neoadjuvant therapy is anti-tumor treatment given before surgery. This drug is also the first and only ADC drug approved globally for neoadjuvant therapy in HER2-positive breast cancer.